TILT Biotherapeutics, Docrates Cancer Center and Helsinki University Hospital Open Cancer Immunotherapy Clinical Trial




HELSINKI, Finland–(BUSINESS WIRE)–TILT Biotherapeutics, a clinical-stage biotechnology company developing cancer immunotherapeutics, announces that it has dosed its first patients and progressed to the second dose level in a monotherapy phase 1 clinical trial of TILT-123, a dual cytokine armed oncolytic adenovirus. The trial is being performed in patients with injectable solid tumors. Patients are being treated at Docrates Cancer Center and Helsinki University Hospital (Helsinki, Finland), le

Source link

Comments are closed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy